HYL001, a new potent TGFβ signaling inhibitor that is efficacious against microsatellite stable CRC metastasis in combination with immune checkpoint therapy in mice
Authors:
- Daniele V. F. TaurielloDTDaniele V. F. Tauriello
- Elena SanchoESElena Sancho
- Carolina Sanchez-ZarzalejoCSCarolina Sanchez-Zarzalejo
- Maria SalvanyMSMaria Salvany
- Ana HenriquesAHAna Henriques
- Sergio Palomo-PonceSPSergio Palomo-Ponce
- Marta SevillanoMSMarta Sevillano
- Xavier Hernando-MomblonaXHXavier Hernando-Momblona
- Joan A. MatarinJMJoan A. Matarin
Preprint
Abstract
Blockade of the TGFβ signalling pathway has emerged from preclinical studies as a potential treatment to enhance the efficacy of immune checkpoint inhibition in advanced colorectal cancer (CRC) and several other types of cancer. However, clinical translation of first-generation inhibitors has known little success. Here, we report the synthesis and characterization of HYL001, a potent inhibitor of TGFβ receptor 1 (ALK5), that is approximately 9 times more efficacious than the structurally related compound galunisertib, while maintaining a favourable safety profile. HYL001 in combination with immune checkpoint blockade (anti-PD1) eradicates liver metastases generated in mice by microsatellite stable, aggressive colorectal cancer tumours at doses where galunisertib is ineffective. GRAPHICALKeywords
This publication has 43 references indexed in Scilit:
- Hyaluronan driven by epithelial aPKC deficiency remodels the microenvironment and creates a vulnerability in mesenchymal colorectal cancerCancer Cell, 2022
- Microbiota-dependent activation of the myeloid calcineurin-NFAT pathway inhibits B7H3- and B7H4-dependent anti-tumor immunity in colorectal cancerImmunity, 2022
- Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer ImmunotherapyBioDrugs, 2022
- High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic reviewCancer Treatment Reviews, 2021
- Stromal SOX2 Upregulation Promotes Tumorigenesis through the Generation of a SFRP1/2-Expressing Cancer-Associated Fibroblast PopulationDevelopmental Cell, 2020
- 1453P Safety and efficacy of vactosertib, a TGF-βR1 kinase inhibitor, in combination with paclitaxel in patients with metastatic gastric adenocarcinomaAnnals of Oncology, 2020
- Transforming Growth Factor-β Signaling in Immunity and CancerImmunity, 2019
- Simultaneous Loss of Both Atypical Protein Kinase C Genes in the Intestinal Epithelium Drives Serrated Intestinal Cancer by Impairing ImmunosurveillanceImmunity, 2018
- Dependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis InitiationCancer Cell, 2012
- The Preparation of 4-MethylquinolinesJournal of the American Chemical Society, 1945